Introduction:
The biologics market in Japan is expected to experience significant growth by 2026, with an increasing focus on innovative therapies and personalized medicine. According to industry reports, the global biologics market is estimated to reach $400 billion by 2026, with Japan playing a key role in driving this growth. In this report, we will explore the top 10 biologics export revenue in Japan for 2026.
Top 10 Biologics Export Revenue in Japan 2026:
1. Takeda Pharmaceutical Company Limited – Takeda is a leading biopharmaceutical company in Japan, with a strong presence in the global market. In 2026, Takeda’s biologics export revenue is projected to reach $5 billion, solidifying its position as a key player in the industry.
2. Daiichi Sankyo Company, Limited – Daiichi Sankyo is another major player in the biologics market in Japan, with a focus on innovative therapies for various diseases. In 2026, Daiichi Sankyo’s biologics export revenue is expected to surpass $3.5 billion, showcasing its growth potential.
3. Astellas Pharma Inc. – Astellas is known for its expertise in developing biologics for oncology and immunology. With an export revenue of $2.8 billion in 2026, Astellas continues to make significant contributions to the biologics market in Japan.
4. Chugai Pharmaceutical Co., Ltd. – Chugai is a subsidiary of Roche Group, specializing in biopharmaceuticals. In 2026, Chugai’s biologics export revenue is estimated to be around $2.5 billion, reflecting its strong performance in the industry.
5. Eisai Co., Ltd. – Eisai is a global pharmaceutical company with a focus on neurology and oncology. With a biologics export revenue of $2 billion in 2026, Eisai remains a key player in the Japanese biologics market.
6. Otsuka Pharmaceutical Co., Ltd. – Otsuka is known for its innovative biologics for mental health and cardiovascular diseases. In 2026, Otsuka’s biologics export revenue is projected to reach $1.8 billion, showcasing its growth potential in the market.
7. Kyowa Kirin Co., Ltd. – Kyowa Kirin specializes in biopharmaceuticals for rare diseases and oncology. With a biologics export revenue of $1.5 billion in 2026, Kyowa Kirin continues to expand its presence in the global market.
8. Shionogi & Co., Ltd. – Shionogi is a Japanese pharmaceutical company with a focus on infectious diseases and metabolic disorders. In 2026, Shionogi’s biologics export revenue is expected to exceed $1 billion, highlighting its contributions to the industry.
9. Mitsubishi Tanabe Pharma Corporation – Mitsubishi Tanabe is a leading biopharmaceutical company in Japan, with a strong portfolio of biologics for various therapeutic areas. With an export revenue of $900 million in 2026, Mitsubishi Tanabe remains a key player in the market.
10. Nippon Shinyaku Co., Ltd. – Nippon Shinyaku is known for its biologics for autoimmune diseases and inflammatory conditions. In 2026, Nippon Shinyaku’s biologics export revenue is projected to reach $800 million, showcasing its growth potential in the industry.
Insights:
The biologics market in Japan is poised for significant growth in the coming years, driven by increasing investments in research and development, as well as a growing demand for innovative therapies. With a projected market size of $10 billion by 2026, Japan is expected to play a key role in shaping the global biologics market. Companies like Takeda, Daiichi Sankyo, and Astellas are leading the way in driving innovation and expanding their presence in the international market. As personalized medicine and targeted therapies continue to gain traction, the biologics market in Japan is expected to witness further growth and development in the years to come.
Related Analysis: View Previous Industry Report
